Endocrine disorders in kidney disease : diagnosis and treatment /

Endocrine disorders in kidney disease : diagnosis and treatment /

Saved in:
Bibliographic Details
Imprint:Cham, Switzerland : Springer, [2019]
Description:1 online resource (346 pages)
Language:English
Subject:
Kidneys -- Diseases -- Endocrine aspects.
Kidney Diseases.
Endocrine System Diseases.
Electronic books.
Format: E-Resource Book
URL for this record:http://pi.lib.uchicago.edu/1001/cat/bib/11852077
Hidden Bibliographic Details
Other authors / contributors:Rhee, Connie M., editor.
Kalantar-Zadeh, Kamyar, editor.
Brent, Gregory A., editor.
ISBN:9783319977652
3319977652
3319977636
9783319977638
9783319977645
3319977644
9783319977638
9783030273576
3030273571
Digital file characteristics:text file PDF
Notes:Triiodothyronine and Reverse Triiodothyronine in CKD
Includes bibliographical references and index.
Print version record.
Summary:This comprehensive book examines the complex interplay between endocrine and kidney disorders, and how this inter-relationship impacts patients with chronic kidney disease. Authored by experts in areas of endocrinology and nephrology, chapters cover a variety of topics, including diabetes, metabolic syndrome, thyroid dysfunction, gonadal disorders, dyslipidemia, mineral bone disorders, obesity, and pituitary disorders. These comorbidities are thoroughly examined and provide the clinician, researcher, and trainee with a greater understanding of the impact of endocrine disorders on kidney disease patients, the ability to identify persistent gaps in knowledge for future investigation, and move closer towards the goal of improving the health and survival of the chronic kidney disease population.
Other form:Print version: Rhee, Connie M. Endocrine Disorders in Kidney Disease : Diagnosis and Treatment. Cham : Springer, ©2019 9783319977638
Standard no.:10.1007/978-3-319-97765-2
10.1007/978-3-319-97
Table of Contents:
  • Intro; Preface; Contents; Contributors; Part I: Diabetes, Insulin Resistance, and the Metabolic Syndrome; 1: Insulin Resistance and the Metabolic Syndrome in Kidney Disease (e.g., the Cardiorenal Metabolic Syndrome); Introduction; Definition(s) of the Cardiorenal Metabolic Syndrome; Epidemiology of the Cardiorenal Metabolic Syndrome; The Cardiorenal Metabolic Syndrome and CKD; Insulin Resistance/Hyperinsulinemia; Inflammatory Cytokines; Inappropriate Activation of the RAAS; Endothelial Dysfunction; Conclusions and Perspectives; References; 2: Diabetic Kidney Disease; Epidemiology
  • PathophysiologyNatural History; Diagnosis; Prevention and Treatment; Complications of Chronic Kidney Disease; Conclusions; References; 3: Glucose Homeostasis and the Burnt-Out Diabetes Phenomenon in Patients with Kidney Disease; Introduction; Glucose Homeostasis in Kidney Disease; Clearance of Insulin; Hypoglycemia Due to Antidiabetic and Other Agents; Decreased Gluconeogenesis in the Kidney; Insulin Secretion and Insulin Resistance; Protein-Energy Wasting (PEW); Burnt-Out Diabetes Phenomenon; Hemodialysis-Related Hypoglycemia and Hyperglycemia; Hemodialysis-Induced Hypoglycemia
  • Metabolic Effects Associated with Glucose-Free DialysateHemodialysis-Associated Hyperglycemia; Insulin Removal by Hemodialysis; Hemodialysis-Associated Hyperglycemia Resembling the Somogyi Effect; References; 4: Glycemic Metrics and Targets in Kidney Disease; Introduction; Glycemic Metrics and Their Role in Kidney Disease; Glycated Hemoglobin (A1C); Glycated Albumin (GA); Fructosamine; 1,5-Anhydroglucitol (1,5-AG); Continuous Glucose Monitoring (CGM); Glycemic Targets in Kidney Disease; Conclusion; References; 5: Diabetic Pharmacotherapies in Kidney Disease; Introduction; Biguanides
  • SulfonylureasMeglitinides; Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs); Dipeptidyl Peptidase IV (DPP-4) Inhibitors; Thiazolidinediones; Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors; Alpha-Glucosidase Inhibitors; Bromocriptine; Bile Acid Resins; Insulin; Amylin Analog; Impact of Antihyperglycemic Agents on Renal Function; Conclusion; References; 6: Diabetes Mellitus and Renal Transplantation; Introduction; Changes in Glucose Homeostasis During Peri-Kidney Transplantation; Changes in Glucose Homeostasis During the Immediate Posttransplant Period
  • New-Onset Diabetes After Kidney TransplantationClinical and Economic Significance of NODAT; It Is Important to Decrease the Incidence of NODAT; Timing of NODAT; Pathogenesis of NODAT; Can Lifestyle Modification Be Adapted for Prevention of NODAT?; Drugs for Preventing NODAT; Conclusion; References; Part II: Thyroid Dysfunction; 7: Evaluating Thyroid Function Tests in Patients with Kidney Disease; Introduction; TSH Measurement; TSH Levels in Chronic Kidney Disease Patients; Measuring Free Thyroxine and Free Triiodothyronine; Thyroxine (T4) Changes with CKD

Similar Items